Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017

Autor:	Yi-Mo Deng, Thomas Tran, James E Fielding, Don Teng, Kylie S Carville, Monique Chilver, Nigel Stocks, Naomi Komadina, Vivian K.Y. Leung, Geoff Higgins, Cara A Minney-Smith, Sheena G. Sullivan, Kristina A Grant
Jazyk:	angličtina
Rok vydání:	2017
Předmět:	0301 basic medicine Male 0302 clinical medicine Influenza A Virus H1N1 Subtype Interim Epidemiology Outcome Assessment Health Care Medicine 030212 general & internal medicine Young adult Child Aged 80 and over Vaccination Middle Aged vaccines and immunisation Influenza Vaccines Child Preschool surveillance RNA Viral epidemiology Female Seasons influenza Rapid Communication Adult medicine.medical_specialty Adolescent Influenza vaccine viral infections 030106 microbiology 03 medical and health sciences Young Adult Virology Influenza Human Humans Vaccine Potency Aged business.industry Influenza A Virus H3N2 Subtype Public Health Environmental and Occupational Health Australia Sequence Analysis DNA influenza-like illness - ILI Confidence interval Influenza B virus Vaccines Inactivated business Laboratories Sentinel Surveillance Demography
Zdroj:	Eurosurveillance
ISSN:	1560-7917 1025-496X
Popis:	In 2017, influenza seasonal activity was high in the southern hemisphere. We present interim influenza vaccine effectiveness (VE) estimates from Australia. Adjusted VE was low overall at 33% (95% confidence interval (CI): 17 to 46), 50% (95% CI: 8 to 74) for A(H1)pdm09, 10% (95% CI: -16 to 31) for A(H3) and 57% (95% CI: 41 to 69) for influenza B. For A(H3), VE was poorer for those vaccinated in the current and prior seasons.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7809ead9f2cb52db48a56f6af5268609 http://europepmc.org/articles/PMC5718387 Zobrazit plný text záznamu